← FDA DRUG APPROVALS

FDA ANDA · ANDA077917

PRAVASTATIN SODIUM

Sponsor: CHARTWELL RX

APPLICATION
ANDA077917
TYPE
ANDA
ORIGINAL APPROVAL
2008-01-08
LATEST ACTION
2025-03-17
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

PRAVASTATIN SODIUMPrescription
PRAVASTATIN SODIUM 40MG · TABLET · ORAL
PRAVASTATIN SODIUMPrescription
PRAVASTATIN SODIUM 10MG · TABLET · ORAL
PRAVASTATIN SODIUMPrescription
PRAVASTATIN SODIUM 80MG · TABLET · ORAL
PRAVASTATIN SODIUMPrescription
PRAVASTATIN SODIUM 20MG · TABLET · ORAL

Approval history

2025-03-17Labeling · Supplement 22 · standardAP
2022-10-13Labeling · Supplement 21 · standardAP
2021-02-01Labeling · Supplement 19 · standardAP
2017-07-11Labeling · Supplement 17 · standardAP
2014-11-03Manufacturing (CMC) · Supplement 16 · unknownAP
2013-04-18Labeling · Supplement 15 · standardAP
2008-06-16Labeling · Supplement 2AP
2008-01-08OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →